Torrent Pharma on January 24 reported a 13.54 percent jump in net profit at Rs 503 crore in the quarter ended December 31, compared to Rs 443 crore in the year-ago period, the company said in an exchange filing.
The pharmaceutical firm’s net profit stood at Rs 453 crore in the September quarter, the stock filing showed.
The shares of the company closed 0.45 percent lower at Rs 3,248.9 on NSE.
Moreover, the company also announced an interim dividend of Rs 26 per equity share of Rs 5 fully paid-up.
The firm’s net sales rose marginally to Rs 2,762 crore in the reported quarter, over Rs 2,691 crore in the same period of the previous financial year, the filing showed. The net sales was recorded at Rs 2,831 crore in the September quarter, the firm said.
The firm said its robust India business traction was offset by CMO shutdown and BRL depreciation of 17 percent on-year. The company statement further said that there was “no insulin CMO sales in the quarter and dispatches were restarted from January 2025”.
The company said its India revenues stood at Rs 1,581 crore, recording an increase of 12 percent led by outperformance in focus therapies.
“On a MAT basis Torrent has outperformed the market across focused therapies aided by strong new launch performance. Torrent has 20 brands in the Top 500 brands in IPM, with 13 brands more than 100 crores.”
Additionally, its US business revenues were at Rs 271 crore, down by 1%. In constant currency terms, the revenue stood at $32 million, down by 3% compared to same period in the previous year.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
